Treatment of Severe or Life-Threatening Pulmonary Sporotrichosis

Clinical Scenario

This protocol addresses pulmonary sporotrichosis presenting in a severe or life-threatening form — a high-acuity subset requiring urgent, intensive antifungal management distinct from milder pulmonary or cutaneous presentations.

Treatment Approach — Partial Overview

Initial management relies on an intravenous antifungal agent; once a favorable clinical response is established, therapy transitions to an oral agent for an extended maintenance course. For certain presentations of localized pulmonary disease, surgical intervention may be combined with antifungal treatment.

The complete regimen — agent selection, sequencing, duration, and additional options — is available in the full structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1086/522765

For severe or life-threatening pulmonary sporotrichosis, amphotericin B, given as a lipid formulation at 3–5 mg/kg daily, is recommended (B-III). Amphotericin B deoxycholate, administered at a dosage of 0.7–1.0 mg/kg daily, could also be used (B-III).

After the patient has shown a favorable response to amphotericin B treatment, therapy can be changed to itraconazole administered at a dosage of 200 mg orally twice daily to complete a total of at least 12 months of therapy (B-III).

Surgery combined with amphotericin B therapy is recommended for localized pulmonary disease (B-III).

View source ↗